ASM Microbe
ASM Microbe
June 19, 2016
5 min watch

VIDEO: Mel Spigelman, MD, discusses TB drug pipeline

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

BOSTON — Mel Spigelman, MD, president and CEO of TB Alliance, discusses the drug development pipeline for tuberculosis here at ASM Microbe 2016. He said that many of the new drugs and regimens developed over the past few years show promise against multidrug-resistant TB, but that novel treatments are still necessary.

“We still need a lot more work, and many more new compounds that will eventuate into much better therapeutics,” he said.

Disclosure: Spigelman reports no relevant financial disclosures.